Skip to content
Advertisement

This May 1, 2018, photo shows Merck corporate headquarters in Kenilworth, N.J. The drugmaker will stop developing two potential COVID-19 vaccines after seeing poor results in early-stage studies. The company said Monday, Jan. 25, 2021, that it will focus instead on studying two possible treatments for the virus that also have yet to be approved by regulators. (AP Photo/Seth Wenig) **FILE**

This May 1, 2018, photo shows Merck corporate headquarters in Kenilworth, N.J. The drugmaker will stop developing two potential COVID-19 vaccines after seeing poor results in early-stage studies. The company said Monday, Jan. 25, 2021, that it will focus instead on studying two possible treatments for the virus that also have yet to be approved by regulators. (AP Photo/Seth Wenig) **FILE**

Featured Photo Galleries